Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
| Publié dans: | Clinical immunology (Orlando, Fla.). - 1999. - 232(2021) vom: 03. Nov., Seite 108871 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | , , , , , , , , , , , , |
| Format: | Article en ligne |
| Langue: | English |
| Publié: |
2021
|
| Accès à la collection: | Clinical immunology (Orlando, Fla.) |
| Sujets: | Journal Article Research Support, Non-U.S. Gov't COVID-19 Convalescent donor Half-life Neutralising antibodies SARS-CoV-2 Antibodies, Neutralizing Antibodies, Viral |
| Résumé: | Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved. Despite the burgeoning field of coronavirus disease-19 (COVID-19) research, the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibodies remains unclear. This study validated two high-throughput immunological methods for use as surrogate live virus neutralisation assays and employed them to examine the half-life of SARS-CoV-2 neutralising antibodies in convalescent plasma donations made by 42 repeat donors between April and September 2020. SARS-CoV-2 neutralising antibody titres decreased over time but typically remained above the methods' diagnostic cut-offs. Using this longitudinal data, the average half-life of SARS-CoV-2 neutralising antibodies was determined to be 20.4 days. SARS-CoV-2 neutralising antibody titres appear to persist in the majority of donors for several months. Whether these titres confer protection against re-infection requires further study and is of particular relevance as COVID-19 vaccines become widely available |
|---|---|
| Description: | Date Completed 30.11.2021 Date Revised 28.03.2023 published: Print-Electronic Citation Status MEDLINE |
| ISSN: | 1521-7035 |
| DOI: | 10.1016/j.clim.2021.108871 |